Index

Note: Page numbers with italicized f’s, t’s, and b’s refer to figures, tables, and boxes, respectively.

Absorption, 48
Acamprosate, 274, 285–8, xiv
Accidents, 33–4, 116
Acetaldehyde, xiv
Acetate, xiv
Acetylcholine, 56
Action plan, 141
Action teams, 141
Activities, in HEADSS framework, 199
Acute tolerance, 73–4
Adolescence, 69–71, 201–3
alcohol exposure in, 75–9
alcohol use disorders and, 75–6
dependence and, 75–6
long-term outcome of, 75–9
neurobehavioral alterations, 78
neurocognitive alterations, 76–8
alcohol treatment in, 329–34
alcohol use in, 3–13, 68–9, 305–11
animal models, 69–70
brain development, 69–71, 201
brief interventions, 153–63
development stages, 201–3
evolutionary roots, 69–70
Adolescent Alcohol Involvement Scale, 215r
Adolescent Diagnostic Interview, 218r
Adolescent Drinking Index, 215r
Adolescent Drinking Inventory, 264
Adolescent Drug Abuse Diagnosis, 217r
Adolescent Obsessive–Compulsive Drinking Scale, 215r
Adolescent Problem Severity Index, 217r
Adolescent Self-Assessment Profile, 217r
Adolescents, 3–13
alcohol use assessment, 204–8
age of onset, 205–6
alcohol-related consequences, 206–7
drinking patterns, 206
information from multiple sources, 207–8
polysubstance use, 207
alcohol use in, 3–13
age of onset, 7r
childhood influences, 4–5
consequences of, 12–13
cross-national comparison, 5–8
drinking patterns, 5–8
gender gap, 10–11
alcohol withdrawal in, 241
binge drinking, 232
Adoption studies, 84–5
Adrenal medulla, 57
Adrenaline, 57
Advertising, 5, 117–18
AER Center for Alcohol Policy Research, 148
AERC Alcohol Academy, 148
Affordability, 112
Age, minimum, 114–15
Age of onset, 6–7, 7r, 37–8, 205–6
Alcohol, 47–51
absorption, 48
advertising of, 117–18
availability of, 115–17
consumption, 106
distribution throughout the body, 48
after effects of, 53–5
blackouts, 54
hangover, 53–4
as gateway substance, 37
harm and, 106–8
hormones and, 57
intoxication, 51–3
laboratory tests, 62–3
long-term effects of, 57–62
dependence, 57–61
diseases, 62
withdrawal, 61–2

Young People and Alcohol: Impact, Policy, Prevention, Treatment, First Edition.
Edited by John B. Saunders and Joseph M. Rey.
© 2011 Blackwell Publishing Ltd. Published 2011 by Blackwell Publishing Ltd.
Alcohol (Continued)
marketing of, 117–18
metabolism, 48–9, 234–5
neurotransmission and, 55–7
patient confidentiality, 242
pharmacological effects, 50–51
Alcohol abuse
consequences of, 232–3
cost of, 21
definition of, xiv–xv
DSM-IV criteria, 214
Alcohol and Drug Problem Acknowledgement Scale, 215
Alcohol and Drug Proneness Scale, 215
Alcohol dehydrogenase (ADH), 48–50, 93, xiv
Alcohol dependence, 57–61
brain stress systems, 60
comorbidity between alcohol and drug use, 89
definition of, xv
DSM-IV criteria, 214
impaired inhibition, 60–61
medications for, 271–94
baclofen, 292
disulfiram, 293
gamma-aminobutyric acid-B receptor agonist, 292
glutamate, 285–92
naltrexone, 281–5
serotonin reuptake inhibitors, 285–92
serotonin-1A partial receptor agonist, 276
serotonin-2 receptor antagonist, 280–81
serotonin-3 receptor antagonists, 275–8
neurobiology of, 58–61
neuronal pathways, 273f
reward systems, 58–9
risk factors, 57–8
schematic representation of, 60f
Alcohol Education and Research Council, 148
Alcohol effects, 32–40
accidents, 33–4
age of onset, 37–8
aversive, 72–3
clinical interview, 206–7
on cognition, 71–2
dependence, 57–61
diseases, 62
on executive functions, 71–2
gateway drug, 37
intoxicating, 72–3
long-term, 57–62
obesity, 36–7
on memory, 71–2
pregnancy, 34–5
rewarding, 72
-risky sexual behavior, 34–5
sexual assault, 35–6
sexually transmitted infections (STI), 34–5
social facilitation, 72
violence, 35–6
withdrawal syndrome, 61–2
Alcohol Epidemiology Program (AEP), 148–9
Alcohol Expectancy Questionnaire-Adolescents, 218
Alcohol insensitivities
alcohol use disorders and, 74–5
tolerance development, 73–4
Alcohol misuse, xv
Alcohol poisoning, 12, 233–4. See also Intoxication
initial management, 235–41
mental health problems and, 242
responses, 237–40
ambulance officers, 240
emergency medical personnel, 240
parents, 237–8
peers, 237–8
Alcohol policies, 110
Alcohol servers/retailers, 128
Alcohol Time Line Follow-Back, 219
Alcohol use disorders, 212–24
adolescent alcohol exposure, 75–6
assessment of, 212–14
assessment instruments, 215–19
biomarkers, 223–4
comorbidity, 334–7
-attention deficit hyperactivity disorder, 335–6
-conduct disorder, 334–5
-mood disorders, 336–7
-comprehensive measures, 220–22
diagnostic interviews, 221–22
heritability of, 87–8
neurocognitive alterations, 76
psychosocial treatments, 258–68
brief interventions, 263
cognitive behavioral therapy, 262–3
family therapy, 260
motivational interviewing, 263–5
multisystemic therapy, 260–61
screening instruments, 220
shifts in alcohol sensitivities, 74–5
treatments, 329–34
cognitive behavioral therapy, 331
contingency management, 331
evidence-based behavioral, 329–32
family therapy, 332–4
general patterns and factors, 329
matching, 330r
motivational interviewing, 329–31
therapeutic communities, 333–4
twelve-step programs, 332–3
validity of self-reports, 222–3
young people vs. adults, 309–11
Alcohol Use Disorders Identification Test, 215r, 220, xv
Alcohol withdrawal, xv
AlcoholEdu, 183
Index 349

Alcoholics Anonymous, 308–23, xiv
resources, 323
roles of clinicians, 318–20
twelve-step facilitation interventions, 320
implementation, 322
interpretation/therapeutic outcome, 321
twelve-step meetings, 312–18
attendance rates, 312–14
correlates, 314–15
cost-effectiveness, 317–18
predictors, 314–315
substance use outcomes, 315–16
summary of studies, 313
youth participation in, 311–18
Alcoholism, type A, 276, xxvi
Alcoholism, type B, 276, xxvii
Alcopops, 11
Aldehyde dehydrogenase (ALDH), 48–50
Allele, xv
Ambulance officers, 240
American Psychiatric Association, 241
Amino acids, xv
Amnesia, 54
Amnesty policies, 185–6
Amperozide, 281
Amphetamines, 207
Amygdala, 59
Anderson model of health services utilization, 329, xv
Antidiuretic hormone, 57
Aspartate aminotransferase (AST), 223
Assortive mating, xxi
Atomoxetine, 336
Attention deficit hyperactivity disorder (ADHD), 23–4, 355–6, xv
Australia
alcohol-attributable costs in, 107
community-based intervention in, 132
drink-driving law in, 116
Autosomes, 92b
Baclofen, 292–3, xv
BASICS (Brief Alcohol Screening and Intervention for College Students), 184–5, 274–5
Behavior change counseling (BCC), 155
Behavioral inhibition, xv
Behavioral therapy, 261–3
Behavioral undercontrol, 22–3, xvi
Binge drinking, 11–12, 114, 172, 232, xvi
Biomarkers, 223–4
Bipolar disorder, 337
Blackouts, 54
Blood alcohol concentration (BAC), 48, 49f, 50, 52r, 53, 54, 116–17, 223, 238r, xvi
Blood glucose, low level of, 54
Botellón, 9
Brain development, 66–80
adolescence and, 69–71
adolescent alcohol exposure and, 75–8
alcohol sensitivity and, 71–5
alcohol use disorders, 74–5
cognition, 71–2
executive functions, 71–2
intoxicating/aversive effects, 72–3
memory, 71–2
rewarding effects, 72
social facilitation, 72
tolerance development, 73
alcohol use during adolescence, 68–9
fetal alcohol exposure, 67–8
transformations in adolescent brain, 70
vulnerable periods, 66–7
Brain stress systems, 60
Brazil
alcohol-related deaths in, 116
community-based intervention in, 132
drink-driving law in, 116
Breathalyzer, 223
Brief Alcohol Screening and Intervention for College Students (BASICS), 184–5, 274–5
Brief interventions, 153–63
for alcohol use disorders, 263
in educational settings, 156–7
electronic forms, 158–9
evidence base for, 156–9
in health settings, 157–8
resources, 161
technological developments in, 155–6
theory and practice, 154–5
Bupropion, 336
Buspirone, 280, xvi
C57BL/6 mouse, xvi
Calcium ions, 56
Canada
binge drinking in, 232
cancer, 89, 207
carbohydrate-deficient transferrin (CDT), 63, 223
catalase, 49f
caudate, 68
center for alcohol marketing to youth, 149
center for applied research solution, 149
cerebellum, 67
childhood influences, 4–5
centered resilience, 26–7
children-of-twins (COT) design, 86–7
choline deficiency, 62
christchurch health and development study (CHDS), 33
chromosomes, 92–3, 92b
circumstances, motivation, readiness and suitability, 218r
Circumstances, Motivation, Readiness and Suitability, 218r

China, drink-driving law in, 116
Choline deficiency, 62
Christchurch Health and Development Study (CHDS), 33
Chromosomes, 92–3, 92b
Circumstances, Motivation, Readiness and Suitability, 218r

C57BL/6 mouse, xvi
Calcium ions, 56
Canada
binge drinking in, 232
cancer, 89, 207
carbohydrate-deficient transferrin (CDT), 63, 223
catalase, 49f
caudate, 68
center for alcohol marketing to youth, 149
center for applied research solution, 149
cerebellum, 67
childhood influences, 4–5
centered resilience, 26–7
children-of-twins (COT) design, 86–7
choline deficiency, 62
christchurch health and development study (CHDS), 33
chromosomes, 92–3, 92b
circumstances, motivation, readiness and suitability, 218r

Circumstances, Motivation, Readiness and Suitability, 218r
Index

Classical conditioning, 72
Clinical interview, 197–210. See also Interventions
adolescence development, 201–3
alcohol use assessment, 204–8
age of onset, 205–6
alcohol-related consequences, 206–7
drinking patterns, 206
information from multiple sources, 207–8
polysubstance use, 207
areas to explore with parents/family, 208
confidentiality, 200–201
counseling, 207–8
formulation, 209
holistic approach, 198
information-gathering in, 198–9
motivational, 209–10
opening, 197
physical examination, 208–9
psychosocial assessment, 199–200
psychosocial risk screening, 203, 204
rapport, 197–8
Cocaine, 89, 207
Cocaine Anonymous, xvi
Cognition, 71–2
Cognitive-behavioral therapy (CBT), 155, 184–5, 262–3, 331
Collaborative Study on the Genetics of Alcoholism, 92
College Alcohol Problem Scale-Revised, 215
College drinking, 180–6. See also Youth drinking
amnesty policies, 185–6
community and campus strategies, 180–82
individual and group interventions, 183–4
ineffective interventions, 182–3
mandated students, 186
online interventions, 183
risk factors, 179–80
College students, 173–4
Coma, 233
COMBINE trial, 283, 331
Communities Mobilizing for Change on Alcohol, 124, 130, 135r, 148
Community Trials Intervention, 124
Community Trials Intervention to Reduce High Risk Drinking, 148
Community Trials Project, 130
Community-based intervention, 122–47. See also Interventions; Prevention
community mobilization in, 137–42
components of, 137
context, 127
evidence, 126–36
examples of, 131, 132–6
features of, 131–6
foci, 127–9
goals, 127, 129–30
implementing, 136–47
Internet sources, 148–9
interventions, 127, 130
key points, 142
policies, 142, 143–5r
scope, 130–31
sources of influence, 126
targets, 127
Comorbidity, 88–90
in adolescence, 328
alcohol and drug use/abuse/dependence, 89, 328
in alcohol use disorders, 334–7
attention deficit hyperactivity disorder, 335–6
conduct disorder, 334–5
mood disorders, 336–7
genes and, 94–5
genetics and, 94–5
with psychiatric disorders, 90
Composite International Diagnostic Interview-Substance Abuse Module, 218
Comprehensive Addiction Severity Index, 217
Conditioning, 72
Conduct disorder, 334–5, xvi
Confidentiality, 200–201
Consumption, 106
level and pattern of, 107–8
social influences on, 108
Contingency management, 265–7
Corpus callosum, 68
Corticotropin releasing factor (CRF), 60
Cortisol, 57
Cosegregate, xvi
Costs, alcohol-attributable, 107
Cotinine, xvi
CpG (C-phosphate-G), 96
CRAFFT, 216
Customary Drinking and Drug Use Record, 218
Cytochrome P450, 50, xvii
Danish house party, 9–10
Days of sale, 116
Deaths, alcohol-related, 107
Delirium tremens, 61
Denmark
drinking culture in, 9–10
ever or very occasional drinking in, 19
Deoxy-ribonucleic acid (DNA), 92b
Department for Children, Schools, and Families, 248
Dependence, 57–61
brain stress systems, 60
comorbidity between alcohol and drug use, 89
DSM-IV criteria, 214r
heritability of, 88
impaired inhibition, 60–61
medications for, 271–94
baclofen, 292
disulfiram, 293
gamma-aminobutyric acid-B receptor agonist, 292
Index

351

glutamate, 285–92
naltrexone, 281–5
serotonin reuptake inhibitors, 278–80
serotonin-1A partial receptor agonist, 276
serotonin-2 receptor antagonist, 280–81
serotonin-3 receptor antagonists, 275–8
neurobiology of, 58–61
neuronal pathways, 273
reward systems, 58–9
risk factors, 57–8
schematic representation of, 60f
Depot naltrexone, 284–5
Depression, 199, 336–7
Dextroamphetamine, 336
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR), 53, 59t, 214t, 328, xvii
Diagnostic Interview Schedule for Children Version IV, 218t
Diagnostic interviews, 221–2
Disability-adjusted life years (DALYs), 107, 123, 153
Disinhibition, 22–3, 73
Disulfiram, 274, 293, 331, xvii
Dirzygotic/fraternal (DZ) twins, 85–6, 91–4, xvii
Dominance, xvii
Dopamine, 56, 58, 273f, xvii
Drink-driving laws, 116
Drinking age, 6, 114–15
Drinking culture, 5–6
Drinking patterns, 5–8, 206
Driving under the influence (DUI), xvii
Drug Avoidance Self-Efficacy Scale, 218t
Drug use, 89, 199, 207
Drug Use Screening Inventory-Revised, 216t
Dry pattern, of drinking, 5, xvii
Duodenum, 48
Early adolescence, 202t
Early detection of alcohol consumption (EDAC) test, 224
Early onset drinking, 18–27
definition of, 18–21, xvii
as developmental market, 21–22
heritability of, 88
pathways of use and abuse, 21–22
promotive factors, 26–7
protective factors, 26–7
risk factors, 20t, 22–6
alcohol-specific behavioral risks, 25
alcohol-specific environmental risks, 25
attention deficit hyperactivity disorder, 23–4
genetic risk, 25–6
nonspecific environmental factors, 24–5
temperament/behavioral risks, 22
Earned media, xvii
e-Chug, 183
Ecstasy, 207
Education, in HEADSS framework, 199
Effect size, xvii
Effects, of alcohol, 32–40, 57–62
accidents, 33–4
age of onset, 37–8
aversive, 72–3
clinical interview, 206–7
on cognition, 71–2
dependence, 57–61
diseases, 62
on executive functions, 71–2
gateway drug, 37
intoxicating, 72–3
on memory, 71–2
obesity, 36–7
pregnancy, 34–5
rewarding, 72
risk sexual behavior, 34–5
sexual assault, 35–6
sexually transmitted infections (STI), 34–5
social facilitation, 72
violence, 35–6
withdrawal, 61–2
El botellón, 9
Electronic interventions, 183
Emergency department management, 235–7
Emergency medical service (EMS), 235–7, 240
Emerging adults, xviii
Employment, in HEADSS framework, 199
Endogenous opioids, 56–7, 58, 281–5
Endophenotypes, 91, xviii
Environmental factors, nonspecific, 24
Environmental risks, alcohol-specific, 25
Epigenetics, xviii
Epistasis, xviii
Escitalopram, 337
Ethyl alcohol. See Alcohol
European School Survey Project on Alcohol and Other Drugs (ESPAD), 232
European Union, alcohol consumption in, 111
Event related potential (ERP), xviii
Executive functions, 71–2, xviii
Externalizing disorders, 94–5, xviii
Extreme drinking, 11–12
FACE, 149
Families, 5, 247–55
family-focused interventions, 250–53
involvement in response, 249–50
protective factors, 249t
risk factors, 249t
role of, 248–9
Family studies, 84–5
Family therapy, 332–4
Family-based interventions, 260
Fatty acid ethyl esters (FAEEs), 224
Fetal alcohol spectrum disorder (FASD), 67–8, xvii
Fetal alcohol syndrome (FAS), 67–8, xvii
352 Index

FG5974, 281
Finland
- alcohol consumption in, 111
- community-based intervention in, 133r
Fluoxetine, 279, 337, xix
Fluvaxamine, xix
Food and Drug Administration (FDA), 259
Form 90, 219r
FRAMES, 155
France
- alcohol consumption in, 111
- drink-driving law in, 116
Fraternal twins, 85–6
Free media, xvi
Functional family therapy (FFT), xix
Functional magnetic resonance imaging (fMRI), 77, xix
GABRA2 gene, 93–6
Gamma-amino butyric acid (GABA), 55, 59, 60, 71, 93, 273r, xix
Gamma-amino butyric acid-B receptor agonist, 292–3
Gamma-glutamyl transferase (GGT), 62, xix
Gastrulation, 68
Gateway drug, 37
Gene expression, 96
Gene-environment correlation, 90, 95b
Gene-environment interaction, 90, 95–6, xix
Genetic material, 92b
Genetic risks, 25–6
Genetically informative research designs, 84–7
- adoption studies, 85
- children-of-twins, 86–7
- family studies, 84–5
- twin studies, 85–6
Genomics, 91–4
Genotype, xix
Global Appraisal of Individual Needs, 217r
Glutamate, 56, 285–92. See also Medications
- acamprosate, 285–8
- topiramate, 285–92
Glutamyltransferase, 224
Grand mal seizure, 61
Hangover, 53–4
Harm reduction, 118
Health Beliefs Model, xix
Health promotion specialists, 128r
Heavy drinkers, 108
HEEADSSS framework, 199–200
Hepatocytes, xx
Heritability, 87–8
- of alcohol dependence, 88
- of alcohol use disorders, 87–8
- defined, 87
- of early onset drinking, 88
Heroin, 207
Hippocampus, 54, 68, 72, xx
Home, in HEADSSS framework, 199
Homicide, 116
Hormones, 57
Hours of sale, 116
House parties, 9–10
How Much is Too Much, 161
Hypoglycemia, 54
Ibuprofen, 207
Identical twins, 85–6
Ignition interlock, xx
Indicated prevention, xxiv
Indirect marketing, 5
Inhibition, impaired, 60–61
Insensitivities, alcohol
- alcohol use disorders and, 74–5
- tolerance development, 73–4
Internalizing disorders, 95, xx
International Agency for Research on Cancer, 107
International Classification of Diseases (ICD-10), 53, 58, 59r, xx
Interventions, 109–10. See also Prevention
- college drinking, 179–86
- community-based. See Community-based intervention
- family therapy, 260
- family-focused, 250–53
- features of, 131–6
- multisystemic therapy, 260–61
- school prevention/intervention programs, 174–9
- targeted, 109–10
- universal, 109
Interview, 197–210
adolescence development, 201–3
alcohol use assessment, 204–8
- age of onset, 205–6
- alcohol-related consequences, 206–7
- drinking patterns, 206
- information from multiple sources, 207–8
- polysubstance use, 207
- areas to explore with parents/family, 208
- confidentiality, 200–201
- consent, 207–8
- finishing, 209
- formulation, 209
- holistic approach, 198
- information-gathering in, 198–9
- motivational, 209–10
- opening, 197
- physical examination, 208–9
- psychosocial assessment, 199–200
- psychosocial risk screening, 203, 204r
- rapport, 197–8
Intoxication, 51–3, 235–40. See also Alcohol poisoning
- aversive effects, 72–3
- blood alcohol concentration, 52r
Index 353

clinical features, 234t
definition of, 51, 53, xx
initial management, 235–41
mental health problems and, 242
patient confidentiality, 242
responses, 237–40
ambulance offices, 240
emergency medical personnel, 240
parents, 237–8
peers, 237–8
police, 238–9
signs of, 52t
Ireland, binge drinking in, 172
Italy, alcohol consumption in, 111
Laboratory tests, 62–3
Lahti project, 133t
Late adolescence, 202t
Law enforcement, 128t
Lean body mass, xx
Ledermann, Sully, 108
Leeds Dependence Questionnaire, 216t
Legal drinking age, 4t, 6
Legislators, 128t
License, 113, 115
Licensed premises, 118, xx
Lieber, Charles, 62
Life Skills Training, 175
Linkage analysis, xx
Linking the Interest of Families and Teachers (LIFT) program, 174, 177
Liver diseases, 62
Luxembourg, alcohol consumption in, 111
Malaysia, youth drinking in, 19
Mandated students/patients, xx
Marketing of alcohol, 117–18
Mating, assortive, xxi
Mating, random, xxi
Mean cell volume, 63
Medications, 271–94
baclofen, 292
disulfiram, 293
gamma-aminobutyric acid-B receptor agonist, 292
 glutamate, 285–92
interactions with alcohol, 51b
 naltrexone, 281–5
serotonin reuptake inhibitors, 278–80
serotonin-1A partial receptor agonist, 276
serotonin-2 receptor antagonist, 280–81
serotonin-3 receptor antagonists, 275–8
Memory impairments, 54, 71–2
Mental health, 242
Metabolism, 48–50, 234–5
Methamphetamine, 207
Methylphenidate, 336
Microsomes, 49f
Middle adolescence, 202t
Midwest Academy, 140b
Military, alcohol use in, 186–9
availability, 188
heavy drinking, 186–7
history, 186
multimodal programs, 188–9
policies, 187–8
prevention, 187
Minimum drinking age laws, 114–15
Minimum pricing, 112–13, xxi
Minnesota Join Together Coalition to Reduce, 124
Mitochondria, 49f
Monozygotic/identical (MZ) twins, 85–6, 91–4, xxi
Mood disorders, 336–7
Motivational enhancement strategies, 184
Motivational interviewing (MI), 155, 209–10, 263–5, 329, xxi
Motor impairment, 73
Motor vehicle accidents, 12–13, 33–4, 116
Multidimensional Family Therapy, 252t
Multisystemic therapy, 260–61, xxi
 Municipal Alcohol Policy, 133t
Mu-receptor antagonist, 281–5
Muslims, 6
Myelin, 70
Myelination, 70
Naloxone, 281
Naltrexone, 274, 281–5, xxi. See also Medications depot, 284–5
 oral, 281–4
National Institute on Alcohol Abuse and Alcoholism (NIAAA), 179, 241
National Minimum Drinking Age, 6
National Registry of Evidence-based Programs and Practices, 174
Neighborhoods Engaging with Students (NEST) project, 181
Neocortex, 67, xxi
Neuropeptide Y, 60
Neurotransmitters, 55–7
dopamine, 56
endogenous opioids, 56–7
GABA, 55
 glutamate, 56
serotonin, 56
New Zealand, community-based intervention in, 134t
Night-time economy, 12
N-methyl-D-aspartate (NMDA), 56, 71, xxi
Norshared environment, xxi
Noradrenaline, 56–7
Nordic countries, alcohol consumption in, 111
Normal drinkers, 108
Index

Norway
- drink-driving law in, 116
- drinking culture in, 9
Nucleus accumbens, 273, xxii
Number needed to treat (NNT), xxii

Obesity, 36–7
Odds ratio, xxii
Off-license, 113, xxiii
OJJDP Model Programs Guide, 148
Ondansetron, 274, xxiii
One-on-ones, 140, xxiii
Online interventions, 183
Opiates, 207
Opioid receptors, xxiii
Opioids, endogenous, 56–8, 281–5
OPRM1 gene, 283, xxiii
Outcomes, 32–40
- accidents, 33–4
- age of onset, 37–8
- gateway drug, 37
- obesity, 36–7
- pregnancy, 34–5
- risky sexual behavior, 34–5
- sexual assault, 35–6
- sexually transmitted infections (STI), 34–5
- violence, 35–6
Ovaries, 57
Oxidation, xxiii
P300, xxiii
P450 2E1, 49
Parents, 128
Paroxetine, xxiii
Party drugs, 207
Patient confidentiality, 242
Peer groups, 27
Pemoline, 336
Perceived Benefit of Drinking Scale, 219
Personal Experience Inventory, 217
Pharmacotherapy, of alcohol dependence, 271–94
- baclofen, 292
- disulfiram, 293
- gamma-aminobutyric acid-B receptor agonist, 292
- glutamate, 285–92
- interactions with alcohol, 51b
- naltrexone, 281–5
- serotonin reuptake inhibitors, 278–80
- serotonin-1A partial receptor agonist, 276
- serotonin-2 receptor antagonist, 280–81
- serotonin-3 receptor antagonists, 275–8
Phenotype, xxiii
Phosphatidylethanol, 224
Physical examination, 208–9
PKNOX2, 94
Place conditioning, 72
Pleiotropy, xxiii
Poisoning, alcohol, 12, 233–4. See also Intoxication
- initial management, 235–41
- mental health problems and, 242
- responses, 237–40
- ambulance officers, 240
- emergency medical personnel, 240
- parents, 237–8
- peers, 237–8
Police, 128
Polymorphism, xxiii
Portugal, alcohol consumption in, 111
Potentiation, long-term, 72
Power of Parents, The (web site), 149
Preference paradigms, xxiii
Prefrontal cortex, xxiv
Pregnancy, 34–5
Preventing Alcohol Trauma: Community Trial, 135
Preventing Binge Drinking, 149
Prevention, 105–18
- alcohol policies, 110
- availability of alcohol, 115–17
- days/hours of sale, 116
- drink-driving laws, 116–17
- outlets, 115
- college drinking, 179–86
- community-based intervention. See Community-based intervention
definition of, xxiv
marketing of alcohol, 117
military policies, 187–9
minimum drinking age laws, 114–15
pricing policies, 111–14
- affordability, 112
- minimum pricing, 112–13
- price elasticity, 111–12
- price increases, 113–14
- school prevention/intervention programs, 174–9
universal, xxiv
universal vs. targeted interventions, 109–10
Preventive paradox, 109
Price elasticity, 111–12
Primary prevention, xxiv
Privacy, protection of, 242
Problem Oriented Screening Instrument for
Teenagers, 216
Problem Recognition Drinking Scale, 219
Psychiatric disorders, 90
Psychosocial assessment, 199–200
Psychosocial risk, 203, 204
Psychosocial treatments, 258–68
brief interventions, 263
cognitive behavioral therapy, 262–3
contingency management, 265–67
family therapy, 260
motivational interviewing, 263–5
multisystemic therapy, 260–61
Public health, 107
Random mating, xxi
Randomized controlled trial, xxiv
Rapid eye movement (REM) sleep, 54
Receptor, xxiv
Research designs, genetically informative, 84–7
  adoption studies, 85
  children-of-twins, 86–7
  family studies, 84–5
  twin studies, 85–6
Resilient Families Programme (Australia), 252
Responsible beverage server training, xxiv
Restorative sleep, 54
Retailers, 128
Reward systems, 58–9
Ribonucleic acid (RNA), 92b
Risk taking, 22–3
Ritanserin, 280–81, xxiv
Road traffic accidents, 12–3, 33–4, 116
Robert Wood Johnson Foundation, 124
Room, Robin, 130
Rs279871 gene, 95
Russefeiring, 9
Rutgers Alcohol Problem Index, 216
Safer California Universities, 182
Sale of alcohol. See also Prevention
days/hours of, 116
  outlets, 115
SAMSHA Center for Substance Abuse Prevention, 21
Saudi Arabia, drink-driving law in, 116
Saving Lives Project, 135
School and Alcohol Harm Reduction Project, 175–7
School prevention/intervention programs, 174–9
Schools
campus/community interventions, 180–81
  prevention/intervention programs, 174–9
Screening instruments, 220
Seattle Social Development Project, 175
Secondary prevention, xxiv
Seizures, 61
Selective prevention, xxiv
Selective serotonin-reuptake inhibitors, 337, xxv
Sensation seeking, 22–3
Serotonin (5-HT), 56, 275, xxiv
Serotonin reuptake inhibitors, 276
Serotonin-1A partial receptor agonist, 276
Serotonin-3 receptor antagonists, 275–8
Sertraline, 279, xxv
Serum transaminases, 63
Sex chromosomes, 92b
Sexual assault, 35–6
Sexual behavior, 34–5
Sexuality, 199
Sexually transmitted infections (STI), 34–5
Shared environment, xxv
Short tandem repeats (STRs), 92b
Sign posting, 200
Single distribution, 108
Single-nucleotide polymorphism (SNP), 93–4, 95, xxv
Sleep, 54
Social contagion, 108
Social facilitation, 72
Social Host.org, 149
Social workers, 128
South Korea, alcohol-attributable costs in, 107
Spain, drinking culture in, 9
SPARC (Study to Prevent Alcohol-Related
  Consequences), 181
Spirit mixers, 11
Sprague-Dawley rat, xxv
STAD project, 124, 134
  Standard drink, 48, xxv
STARS (Start Taking Alcohol Risks Seriously)
  programme, 252
Strengthening Families Program, 175, 178, 250–53, 252
Stress, 57
Structured Clinical Interview for
  DSM-IV-Adolescent Version, 218
Students, 171–4
  access to alcohol, 173
  alcohol use in, 171–3
  college/university, 173–4
  mandated, 186
  school prevention/intervention programs, 174–9
Study to Prevent Alcohol-Related Consequences
  (SPARC), 181
Substance Abuse and Mental Health Services
  Administration (SAMSHA), 174
Substance Abuse Proclivity Scale, 216
Substance Abuse Subtle Screening
  Inventory-Adolescents, 216
Suicide, 199
Surfer Paradise Safety Action Project, 132
Sweden
  alcohol sales in, 116
  drink-driving law in, 116
  Synapses, 70
Targeted intervention, 109–10
Taste aversion, 73
Taste perversions, xxv
Taxes, 112
Taxons, 68
Teachers, 128
Teen Addiction Severity Index, 217
Tertiary prevention, xxiv
Testes, 57
Testosterone, 57
Index

Thailand, alcohol consumption in, 110
Therapeutic community, 333–4, xxv
Tobacco use, 89, 123
Tolerance, 73–4, 221
Tonic–clonic seizure, 61
Topiramate, 274, 288–92, xxvi
Transaminases, 63
Transfection, xxvi
Treatments, 329–34. See also Medications
of alcohol intoxication, 235–40
cognitive behavioral therapy, 331
contingency management, 331
evidence-based behavioral, 329–32
family therapy, 332–4
general patterns and factors, 329
matching, 330r
motivational interviewing, 329–1
therapeutic communities, 333–4
twelve-step programs, 332–3
of withdrawal syndromes, 241–2
Tremor, 61
Tuberculosis, 107
Twelve-step (12) groups/programs, 332–3, xxvi
Twelve-step (12) meetings, 312–18, xxvi. See also
Alcoholics Anonymous
attendance rates, 312–14
correlates, 314–15
cost-effectiveness, 317–18
predictors, 314–15
substance use outcomes, 315–16
summary of studies, 313r
Twin studies, 85–6
Type A alcoholism, 276, xxvi
Type B alcoholism, 276, xxvi
Underage drinking. See Youth drinking
Underage Drinking Enforcement Training Center, 149
United Kingdom
alcohol-attributable costs in, 107
binge drinking in, 172
drink-driving law in, 116
licensed premises in, 116
teenage drinking in, 172
United States
alcohol intoxication in, 107
alcohol-attributable costs in, 107
community-based intervention in, 134–5
drink-driving law in, 116
early onset drinking in, 19
teenage drinking in, 173
Universal intervention, 109–10
Universal prevention, xxiv
University students, 173–4
Urinalysis, 223
Ventral tegmental area (VTA), 56, 59, 273f
Violence, 35–6
Vivitrex, 284–5
Vivitrol, 284–5, xxvii
Wet pattern, of drinking, 5, xxvii
White matter, 77
Wine drinking, 5
Wistar rat, xxvii
Withdrawal syndrome, 61–2, 241, xv
World Health Organization (WHO), 122–3
Young Adult Alcohol Consequences Questionnaire, 217r
Young Adult Alcohol Problem Screening Test, 216r
Young adulthood, 202r
Youth drinking, 3–13. See also Early onset drinking
age of onset, 7r
alcohol use assessment, 204–8
age of onset, 205–6
alcohol-related consequences, 206–7
drinking patterns, 206
information from multiple sources, 207–8
polysubstance use, 207
binge drinking, 11–12
brief interventions, 153–63
childhood influences, 4–5
consequences of, 12–13
cross-national comparison, 5–8
drinking patterns, 5–8
gender gap, 10–11
night-time economy and, 11–12
outcomes, 32–40
accidents, 33–4
age of onset, 37–8
gateway drug, 37
obesity, 36–7
pregnancy, 34–5
risk sexual behavior, 34–5
sexual assault, 35–6
sexually transmitted infections (STI), 34–5
violence, 35–6
social factors in, 8–10